Bart Main
Child & Adolescent Psychiatry · Hyannis, MANPI 1689770604
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.5% of the total across 75 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 17.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,354, more than ten times the $108 reported in 2020.
Across 75 payments — averaging $31.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$405
- Johnson & Johnson$309
- Teva Pharmaceuticals USA, Inc.$298
- E.r. Squibb & Sons, L.L.C.$267
- AbbVie$145
- Axsome Therapeutics, Inc.$145
- plus $756 from 13 others
What the payments were for
- Food & beverage$2,15092%
- Education$1758%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 13 | $405 |
| Johnson & Johnson | 8 | $309 |
| Teva Pharmaceuticals USA, Inc. | 10 | $298 |
| E.r. Squibb & Sons, L.L.C. | 12 | $267 |
| AbbVie | 6 | $145 |
| Axsome Therapeutics, Inc. | 2 | $145 |
| Ironshore Pharmaceuticals Inc. | 1 | $130 |
| Vanda Pharmaceuticals Inc. | 5 | $123 |
| Sunovion Pharmaceuticals Inc. | 1 | $108 |
| Alkermes, Inc. | 4 | $94 |
| Lundbeck LLC | 3 | $74 |
| Neurocrine Biosciences, Inc. | 2 | $56 |
| Luye Pharma (USA) Ltd. | 2 | $37 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $33 |
| Supernus Pharmaceuticals, Inc. | 1 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $28 |
| Sage Therapeutics, LLC | 1 | $19 |
| Collegium Pharmaceutical, Inc. | 1 | $14 |
| Corium, LLC | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,325 in reported general payments places this provider in the 85th percentile of 104 child & adolescent psychiatry providers in Massachusetts.
See all child & adolescent psychiatry providers in Massachusetts →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lorazepam | 11 | $20 |
Paid to pharmacies, not to this prescriber.
Other child & adolescent psychiatry in Hyannis
- Maitri PatelFramingham$277K
- David DemasoBoston$41K
- Blaise AguirreBelmont$21K
- Matthew SiegelBoston$11K
- Janet WozniakBoston$8K
- Joseph Gonzalez HeydrichBoston$7K
- Michael MarcusBoston$4K
- Ranna ParekhBoston$3K
- Joseph BiedermanBoston$3K
- Ireen AhmedBoston$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.